TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Postoperative visual analogue scale (VAS) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Karolinska interpersonal violence scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Overall response rate in MF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall response rate in PV and ET
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Systolic blood pressure agreement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Diastolic blood pressure agreement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Regulatory immune cell changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Intra-Operative complication rate
Endpoint domain: Adverse events/effects
Primary endpoint: Mechanical Power
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Short-term chronic serious adverse device effect (SADE) rate
Endpoint domain: Adverse events/effects
Primary endpoint: Responder rate at 12 months post implant
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: One-leg standing test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional reaching test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Five-times sit-to-stand test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Partial clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Scoliosis Research Society-22 (SRS-22)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Calculation of plasma levels of hPTH(1-34) AUC0-t
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IBM-Functional Rating Scale (IBM-FRS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: IBM Physical Functioning Assessment (sIFA)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Modified Schober Method
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Emotional labor
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Self-Efficacy
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Sensitivity, specificity, NPV and PPV of Uromonitor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Post Traumatic Epilepsy (PTE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Proportion of patients within the desired FK trough level at first steady state
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients within the desired FK trough level at 7 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection and titration of antibodies against SARS-CoV-2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Timed Up and Go Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Physical functioning
Primary endpoint: 5 Time Sit to Stand Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Academic Score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Vestibular Attributes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time on Task / Attention
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Sensitivity of diagnosis of myocardial infarction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Specificity of diagnosis of myocardial infarction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Kappa statistics of diagnosis of myocardial infarction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Occurrence of Significant Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Connor-Davidson Resilience Scale (CDRS-10)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Arabic Scale of Happiness (ASH-20)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in New General Self-Efficacy Scale (NGSE-8)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Standardized uptake value of 177Lu-AB-3PRGD2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of AHD patients alive and retained in care
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of AHD patients in care and treatment virally suppressed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Rifampin serum area under the concentration time curve for the 24 hour dosing interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical Component Score of the SF-36 questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Production of a novel non-invasive biomarker panel for NAFLD prediction and diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 1-year relapse free survival rate
Endpoint domain: Mortality/survival
Primary endpoint: Anxiety of relatives
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from baseline in pain related functional disability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in gastro symptom related worry
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Participation at 6 months post-stroke
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Knee Injury and Osteoarthritis Outcome Score (KOOS) Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: WESTREN ONTARIO AND MCMASTER UNIVERSITIES OSTEOARTHRITIS INDEX (WOMAC SCALE)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: 36- Items Short Form Survey (SF-36) QUESTIONNAIRE
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in sexual health
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in overall disease activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of refractory headache
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Standard deviation of the position of the center of pressure on the anteroposterior axis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Usable blastocyst rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Response to Lu-PSMA treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Endocrine therapy related musculoskeletal pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Pathogen Concordance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: pathologic complete response (PCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RCB 0-1 Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: amount of urinary leakage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Antibody titer (seroconversion)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of grade 2 / 3 hand foot syndrome
Endpoint domain: Adverse events/effects
Primary endpoint: Nutrition implementation rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Nutrition compliance rate of stroke inpatients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cessation of Gingival Bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Assessment of academic achievement
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: time to ventilatory weaning
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: QEEG as a biomarker of Stress
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of index lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentages of time spent within the TIR glycemic target range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in sex related personal distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in sexual dysfunction
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Evaluation of axillary lymph nodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Human Interactive behaviors during AAT sessions
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Emotional Displays
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Strengths and Difficulties Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Safety of ONIVYDE
Endpoint domain: Adverse events/effects
Primary endpoint: Wisconsin Tobacco Quit Line (WTQL) referral rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Wisconsin Tobacco Quit Line (WTQL) enrollment rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Tobacco use screening of adult consumers of Salvation Army services
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of suicidal behavior
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement of synovitis and enthesitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Durability of the CTI block
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: changes in perfusion index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of rolling per minute
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of Taneasy and Actein in treating COPD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Safety of Taneasy and Actein in treating COPD
Endpoint domain: Adverse events/effects
Primary endpoint: Pupil size (diameter)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Significant arrhythmic burden
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Salivary ACTH levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Incidence of hypoxemia (SpO2 lower than 90%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Cognitive functioning T1
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Cognitive functioning T2
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Cognitive functioning T3
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Percentage of correct answers in melody comparison tasks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Irregular Vaginal Bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Intervention feasibility / fidelity of delivery
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Potential risks of the intervention
Endpoint domain: Adverse events/effects
Primary endpoint: Adequacy of tru-cut biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of lung and breast cancer screening adherence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Electromyography of masticatory muscles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical response to treatment of viral infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence and severity of Non-Alcoholic Fatty Liver Disease (NAFLD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mean slope before ablation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Days Without Hurting or Burning
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Changes in plasma NAD+ levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dental Caries as assessed by DMFS Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oral mucosal lesions coinfection as assessed by the presence or absence of candidiasis, red/white lesions, ulcers and warts intraorally
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life as assessed by the Xerostomia Quality of Life Scale (XeQoLS)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Ctrough for Lenacapavir (LEN) at the End of Week 26
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: General Acceptability of LEN and F/TDF as PrEP
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of participants with adverse reaction
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of participants with serious adverse reaction
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of participants with reactogenicity events
Endpoint domain: Adverse events/effects
Primary endpoint: State of global deterioration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minimental Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: RDRS-2 Rapid Disability Assessment Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in gene expression in Tregs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Functional Outcomes
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Diclofenac area under the concentration vs. time curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diclofenac maximum concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diclofenac renal clearance (CLr)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distance visual acuity (VA) at Year 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distance visual acuity (VA) at Year 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neurological outcome (modified Rankin scale)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: total analgesic consumption
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Incidence, severity, and causality of AEs and serious AEs (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Physical examination abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Vital signs abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of 12-lead ECG abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of Continuous cardiac telemetry abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of Laboratory tests abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Motor tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AAC-Q questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Determination of the Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence and Severity of All Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Safety of therapeutic HCV vaccine
Endpoint domain: Adverse events/effects
Primary endpoint: Change in the inter-2nd premolar width
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean variant allele frequency (VAF) of mutations in ctDNA samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Time of onset of anesthesia to T10
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Time for complete motor block
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Time for first rescue analgesia will be required during surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Surgical R0 resection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Time from hospital admission to medical discharge
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of reminders found
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Proportion of patients continuing allocated treatment
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Microbial features
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of Chronic Kidney Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Evolution of sarcopenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: American Orthopedic Foot and Ankle (AOFAS) score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Breathing rate and apnea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Future evaluation of patients' status post-consultation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Disappearance rate of pseudocyst
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of patients successfully treated for CBD strictures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite Complete Remission Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preoperative radiographic cartilage defect of ipsilateral knee
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Preoperative radiographic meniscal tear of ipsilateral knee
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Preoperative radiographic ligament ruptures of ipsilateral knee
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Foot progression angle during normal gait
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Injection interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in perceived speech effort (PSE)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in smoothed cepstral peak prominence (CPPS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in speech quality vector (SQV) (%)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Porphyrins in Urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Real-World Time to Next Treatment (rwTTNT1)
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Changes in perceived stress
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Spherical equivalent change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in emotional intelligence
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in self-concept
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Peronei muscle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Proportion of subjects with successful reperfusion (mTICI score of 2b or greater)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Occurrence of symptomatic intracerebral hemorrhage (sICH)
Endpoint domain: Adverse events/effects
Primary endpoint: TTH-headache days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in readmission rates
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Duration of hospitalization in intensive care unit
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Change in resting tidal volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes